Generic Name: tenofovir disoproxil fumarate
Company: Gilead Sciences
Approval Status: Approved
Generic Version Available: No
FDA-approved for the treatment of chronic hepatitis B infection in persons who are 12 years and older. (Viread is also used to treat HIV-1.)
- Viread was approved by the U.S. Food and Drug Administration for use by adults with chronic hepatitis B in 2001.
- In clinical studies, up to 76 percent of participants had a therapeutic response after 48 weeks of treatment with Viread.
One 300 mg tablet daily, with or without food. Dosage adjustment may be needed for people with kidney disease.
Pediatric Dose: Age 12 years and older (35 kg or more): one 300 mg tablet daily, with or without food.
Dosing Info: Treatment length is indefinite and depends on clinical outcomes. Do not change your dose or stop taking Viread without talking to your medical provider.
- The most common side effects are nausea, rash, diarrhea, headache, pain, depression and weakness.
- Viread may cause severe liver problems or a serious condition called lactic acidosis (buildup of acid in the blood).
- Viread may cause bone or kidney problems. It may also cause your hepatitis B infection to worsen.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Viread or may require dose adjustments, consult the Viread package insert.
- HIV testing is recommended prior to taking Viread.
- There are no adequate, well-controlled studies in pregnant women who have taken Viread. Viread should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- The safety of breast feeding while taking Viread has not been established, and it is recommended that Viread be discontinued if breast-feeding.
For More Info: http://www.viread.com
Co-Pay Program Info: https://www.hepmag.com/basics/hepatitis-b-basics/paying-hepatitis-b-treatment
Patient Assistance Program Info: https://www.hepmag.com/basics/hepatitis-b-basics/paying-hepatitis-b-treatment
Last Reviewed: December 22, 2021